Novartis Champions Cosentyx With More Long-Term Psoriasis Data

Although its focus may be shifting somewhat towards other indications, the Swiss major has reported study read-outs that demonstrate the long-term efficacy of its IL-17A inhibitor blockbuster in nail and palmoplantar psoriasis.

PS1711_Trumpet Player_196485695_1200
Novartis has been trumpeting the long-term efficacy of Cosentyx for psoriasis • Source: Shutterstock

While pursuing different autoimmune diseases for Cosentyx (secukinumab), Novartis AG has presented more long-term data which the company hopes will consolidate the blockbuster's leading position in its core indication of psoriasis.

The Swiss major has heralded "first-of-its-kind long-term data" showing that Cosentyx provided sustained improvements for up to 2.5 years in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category